Blood Res.  2017 Mar;52(1):44-49. 10.5045/br.2017.52.1.44.

Warm autoimmune hemolytic anemia: experience from a single referral center in Mexico City

Affiliations
  • 1Hematology and Oncology Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico. retriever_g@yahoo.com
  • 2Comprehensive Cancer Center, Médica Sur Clinic and Foundation, Mexico City, Mexico.

Abstract

BACKGROUND
Autoimmune hemolytic anemia (AIHA) is characterized by an autoimmune-mediated destruction of red blood cells. Warm AIHA (wAIHA) represents 60% of AIHA cases and is associated with the positive detection of IgG and C3d in the direct antiglobulin test (DAT). This study aimed to assess the clinical and laboratorial differences between primary and secondary wAIHA patients from a referral center in Mexico City.
METHODS
All patients diagnosed with wAIHA in our institution from January 1992 to December 2015 were included and received corticosteroids as the first-line treatment. We analyzed the response to the first-line treatment, relapse-free survival, and time to splenectomy.
RESULTS
Eighty-nine patients were included. Secondary wAIHA represented 55.1% of the cases. At diagnosis, secondary wAIHA patients showed a DAT mixed pattern more frequently than primary wAIHA patients (36.7 vs. 17.5%, P<0.001). In the survival analysis, patients with secondary wAIHA had a lower time to response (18 vs. 37 days, P=0.05), median disease-free survival (28.51 vs. 50.95 weeks, P=0.018), and time to splenectomy (43.5 vs. 61 wks, P=0.029) than those with primary wAIHA. Due to economic constraints, rituximab was considered as the third-line treatment in only two patients.
CONCLUSION
Secondary wAIHA may benefit from a longer low-dose steroid maintenance period mainly due to its shorter time to relapse and time to splenectomy than primary wAIHA.

Keyword

Autoimmune hemolytic anemia; Warm autoimmune hemolytic anemia; Primary wAIHA; Secondary wAIHA; Direct antiglobulin test

MeSH Terms

Adrenal Cortex Hormones
Anemia, Hemolytic, Autoimmune*
Coombs Test
Diagnosis
Disease-Free Survival
Erythrocytes
Humans
Immunoglobulin G
Mexico*
Recurrence
Referral and Consultation*
Rituximab
Splenectomy
Adrenal Cortex Hormones
Immunoglobulin G
Rituximab

Figure

  • Fig. 1 Time to response to the first-line treatment in patients with primary and secondary wAIHA.

  • Fig. 2 Differences in relapse-free survival between primary and secondary AIHA.

  • Fig. 3 Time-to-splenectomy in patients with primary and secondary AIHA.


Cited by  2 articles

Treatment of autoimmune hemolytic anemia: real world data from a reference center in Mexico
José Carlos Jaime-Pérez, Patrizia Aguilar-Calderón, Lorena Salazar-Cavazos, Andrés Gómez-De León, David Gómez-Almaguer
Blood Res. 2019;54(2):131-136.    doi: 10.5045/br.2019.54.2.131.

Splenic myeloid metaplasia in warm autoimmune hemolytic anemia (wAIHA): a retrospective study
Víctor Manuel Anguiano-Álvarez, Alonso Hernández-Company, Nashla Hamdan-Pérez, Daniel Montante-M, Diego A. Zúñiga-Tamayo, Sergio Rodríguez-Rodríguez, Alan Pomerantz, Elena J. Tuna-Aguilar
Blood Res. 2018;53(1):35-40.    doi: 10.5045/br.2018.53.1.35.


Reference

1. Jaime-Pérez JC, Rodríguez-Martínez M, Gómez-de-León A, Tarín-Arzaga L, Gómez-Almaguer D. Current approaches for the treatment of autoimmune hemolytic anemia. Arch Immunol Ther Exp (Warsz). 2013; 61:385–395. PMID: 23689532.
Article
2. Zanella A, Barcellini W. Treatment of autoimmune hemolytic anemias. Haematologica. 2014; 99:1547–1554. PMID: 25271314.
Article
3. Berentsen S, Sundic T. Red blood cell destruction in autoimmune hemolytic anemia: role of complement and potential new targets for therapy. Biomed Res Int. 2015; 2015:363278. PMID: 25705656.
Article
4. Barros MMO, Blajchman MA, Bordin JO. Warm autoimmune hemolytic anemia: recent progress in understanding the immunobiology and the treatment. Transfus Med Rev. 2010; 24:195–210. PMID: 20656187.
Article
5. Bass GF, Tuscano ET, Tuscano JM. Diagnosis and classification of autoimmune hemolytic anemia. Autoimmun Rev. 2014; 13:560–564. PMID: 24418298.
Article
6. Roumier M, Loustau V, Guillaud C, et al. Characteristics and outcome of warm autoimmune hemolytic anemia in adults: New insights based on a single-center experience with 60 patients. Am J Hematol. 2014; 89:E150–E155. PMID: 24847759.
Article
7. Naik R. Warm autoimmune hemolytic anemia. Hematol Oncol Clin North Am. 2015; 29:445–453. PMID: 26043384.
Article
8. Lechner K, Jäger U. How I treat autoimmune hemolytic anemias in adults. Blood. 2010; 116:1831–1838. PMID: 20548093.
Article
9. Barcellini W, Fattizzo B, Zaninoni A, et al. Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients. Blood. 2014; 124:2930–2936. PMID: 25232059.
Article
10. Crowther M, Chan YL, Garbett IK, Lim W, Vickers MA, Crowther MA. Evidence-based focused review of the treatment of idiopathic warm immune hemolytic anemia in adults. Blood. 2011; 118:4036–4040. PMID: 21778343.
Article
11. Reynaud Q, Durieu I, Dutertre M, et al. Efficacy and safety of rituximab in auto-immune hemolytic anemia: a meta-analysis of 21 studies. Autoimmun Rev. 2015; 14:304–313. PMID: 25497766.
Article
12. Maung SW, Leahy M, O'Leary HM, et al. A multi-centre retrospective study of rituximab use in the treatment of relapsed or resistant warm autoimmune haemolytic anaemia. Br J Haematol. 2013; 163:118–122. PMID: 23909468.
Article
13. Birgens H, Frederiksen H, Hasselbalch HC, et al. A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. Br J Haematol. 2013; 163:393–399. PMID: 23981017.
14. Barcellini W, Zaja F, Zaninoni A, et al. Sustained response to low-dose rituximab in idiopathic autoimmune hemolytic anemia. Eur J Haematol. 2013; 91:546–551. PMID: 24033754.
Article
15. Dierickx D, Verhoef G, Van Hoof A, et al. Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study. J Intern Med. 2009; 266:484–491. PMID: 19549092.
Article
16. Rattarittamrong E, Eiamprapai P, Tantiworawit A, et al. Clinical characteristics and long-term outcomes of warm-type autoimmune hemolytic anemia. Hematology. 2016; 21:368–374. PMID: 27077773.
Article
17. Baek SW, Lee MW, Ryu HW, et al. Clinical features and outcomes of autoimmune hemolytic anemia: a retrospective analysis of 32 cases. Korean J Hematol. 2011; 46:111–117. PMID: 21747883.
Article
18. Zeerleder S. Autoimmune haemolytic anaemia - a practical guide to cope with a diagnostic and therapeutic challenge. Neth J Med. 2011; 69:177–184. PMID: 21527804.
19. Alwar V, Shanthala DA, Sitalakshmi S, Karuna RK. Clinical patterns and hematological spectrum in autoimmune hemolytic anemia. J Lab Physicians. 2010; 2:17–20. PMID: 21814401.
Article
20. Berentsen S. Role of complement in autoimmune hemolytic anemia. Transfus Med Hemother. 2015; 42:303–310. PMID: 26696798.
Article
21. Prabhu R, Bhaskaran R, Shenoy V, G R, Sidharthan N. Clinical characteristics and treatment outcomes of primary autoimmune hemolytic anemia: a single center study from South India. Blood Res. 2016; 51:88–94. PMID: 27382552.
Article
22. Akpek G, McAneny D, Weintraub L. Comparative response to splenectomy in Coombs-positive autoimmune hemolytic anemia with or without associated disease. Am J Hematol. 1999; 61:98–102. PMID: 10367787.
Article
23. Aladjidi N, Leverger G, Leblanc T, et al. New insights into childhood autoimmune hemolytic anemia: a French national observational study of 265 children. Haematologica. 2011; 96:655–663. PMID: 21228033.
Article
Full Text Links
  • BR
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr